Explore the words cloud of the CSC-IS project. It provides you a very rough idea of what is the project "CSC-IS" about.
The following table provides information about the project.
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON
|Coordinator Country||Spain [ES]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-07-01 to 2016-12-31|
Take a look of project's partnership.
|1||FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON||ES (BARCELONA)||coordinator||150˙000.00|
Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, is 14 months and its 5-yr survival less than 5%. It is therefore urgent to develop more effective treatments against this fatal disease.
There are two main reasons that explain the lack of success for the current treatments: In one hand, Cancer Stem cells (CSCs) are responsible from tumour initiation, maintenance, relapse and metastasis. On the other hand, the tumour has mechanisms to repress the patient’s immune system that attacks tumour cells. Our team has discovered a molecular pathway critical in the regulation of CSCs and the immune checkpoint. The project presented here entails the proof of concept and pre-clinical development of a humanized antibody blocking this pathway. At the end of the ERC POC project we will have a patent protected and fully humanized antibody active in vivo and in vitro and ready to enter Phase I clinical trials in humans to continue its commercialization process. The forecasted annual peak revenue for this therapeutic antibody in GBM is $590M with additional sales coming from line extensions in other cancer indications.
With the ERC POC project we are dramatically increasing the commercial value of the therapeutic antibody, transforming an R&D finding (a pathway is critical for cancer) into a potential new solution to patients (a therapeutic antibody). Hence, we are de-risking the product, advancing it through the commercialization path and creating a product and a commercial data package with a good expectative in the cancer market that is ready to be transferred to a spin-off company.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CSC-IS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CSC-IS" are provided by the European Opendata Portal: CORDIS opendata.
Streamlined carbon dioxide conversion in ionic liquids – a platform strategy for modern carbonylation chemistryRead More
Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin DomainsRead More
Redefining the esophageal stem cell niche – towards targeting of squamous cell carcinomaRead More